
Managing Dyslipidemias in Patients With Chronic Kidney Disease



Causes of Death Among Period Prevalent Patients, 1997-1999, Treated with Hemodialysis, Peritoneal Dialysis or Kidney Transplantation



Abbreviations: MI, Myocardial infarction, HD, heart disease

Based on recommendations contained in the K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease

GUIDELINE I

- 1.1 All adults and adolescents* with CKD should be evaluated for dyslipidemias. (B)**
- 1.2 For adults and adolescents with CKD, the assessment of dyslipidemias should include a complete fasting lipid profile with total cholesterol, LDL, HDL, and triglycerides. (B)
- 1.3 For adults and adolescents with Stage 5 CKD, dyslipidemias should be evaluated upon presentation (when the patient is stable), at 2-3 months after a change in treatment or other conditions known to cause dyslipidemias; and at least annually thereafter. (B)

GUIDELINE 2

- 2.1 For adults and adolescents with Stage 5 CKD, a complete lipid profile should be measured after an overnight fast whenever possible.(B)
- 2.2 Hemodialysis patients should have lipid profiles measured either before dialysis, or on days not receiving dialysis. (B)

GUIDELINE 3

Stage 5 CKD patients with dyslipidemias should be evaluated for remediable, secondary causes. (B)

Secondary Causes of Dyshpidenilas				
Radial Conflicts				
Hephrelie symptome	Protective also bel companyitore			
Hypoligeddian	Live chance			
Distate				
Bathallan				
15-cia-rodania edit	Androgene			
Andersectorie	. Dal estimapiles			
Highly with a standard transpo	Certradentite			
Disastica	Cyclospedia			
Bain-Maximu	Sinin: a			


Secondary Causes of Dyslipidemias

* Adolescent is defined by onset of puberty.

** (B) – It is recommended that clinicians routinely follow the guideline. There is moderate evidence that the practice improves net health outcomes.

GUIDELINE 4

- 4.1 For adults with Stage 5 CKD and fasting triglycerides ≥500 mg/dL (≥5.65 mmol/L) that cannot be corrected by removing an underlying cause, treatment with therapeutic lifestyle changes (TLC) and a triglyceride-lowering agent should be considered. (C)⁺
- 4.2 For adults with Stage 5 CKD and LDL ≥100 mg/dL (≥2.59 mmol/L), treatment should be considered to reduce LDL to <100 mg/dL (<2.59 mmol/L). (B)</p>
- 4.3 For adults with Stage 5 CKD and LDL <100 mg/dL (<2.59 mmol/L), fasting triglycerides ≥200 mg/dL (≥2.26 mmol/L) and non-HDL cholesterol (total cholesterol minus HDL) ≥130 mg/dL (≥3.36 mmol/L), treatment should be considered to reduce non-HDL cholesterol to <130 mg/dL (<3.36 mmol/L). (C)</p>



Treatment for Adults

Units for the figure above are in mg/dL. To convert mg/dL to mmol/L, multiply triglycerides by 0.01129 and LDL or non-HDL cholesterol by 0.02586. Abbreviations: TG, triglycerides; TLC, therapeutic lifestyle changes; LDL, low-density lipoportein; HDL, high-density lipoprotein.

⁺ (C) It is recommended that clinicians consider following the guideline for eligible patients. This recommendation is based on either weak evidence, poor evidence or on the opinions of the Work Group and reviewers, that the practice might improve net health outcomes.

Key Feautres of the NKF-K/DOQI Guidelines That Differ from Those of the National Cholesterol Education Program Adult Treatment Panel III

	F-17000 Guideline	Adult Treatment Panel II Galdelines
1.	CRD patients should be considered in be in the highest dak onlegory.	 CKO pollente are not manageti dillementiv from other patiente.
2	Evaluation of dysightenian should occur at presentation with CKD, after a change status, and annually.	 Baluation of cysliplicanies should occur every years.
8.	Drug therapy should be used for LDL 100-129 mg/dL after 9 months of TLC.	 Drug Therapy is considered optional for LDL 100 129 mg/dL.
4.	Initial drug therapy for high LOL should be with a within	 Initial drug therapy for high LDL should be with (statis, bils acid sequestrant, or nicotinic acid.
6.	Recommendations are made for patients <20 years old.	 No recommendations are made for patients <20 years did.
8.	Fibrates may be used in Stage 6 CR3 a) for patients with triglycerbias 2500 mg/dL; and b) for patients with triglycerbias 2500 mg/dL, with non-HDL obtained 2150 mg/dL, who do not islands statistic.	6. Fibraian ara contraindicated in Stage 5 CKD.
7.	Gemilipical may be the fibrate of choice for treatment of high triglycentics in patients with CRD.	 No preferences are indicated for which a fibrate should be used to treat hyperhighyperistants.
AN AN	ooswari angkiil, to arrashii, maliipiy irigiyoorkiwa by 0.811 Irawiadone: NRF-KIDOCI, Maitsari Kishay Foundation K wy olieozas, (.21, Jow-dataliy ijaqarajain chalaniowa); Hi aiyie changaa.	29 and choisebard by 0.02596. Rohey Discusse Coliconte Quality Intitative; (202), chronic CL, high-daratiy Apoprainin choisebard; 77.27, discapaulic

Management of Dyslipidemias in Adults with Chronic Kidney Disease


Dyslipidemia	Goal	Initiate	Increase	Alternative
TG \geq 500 mg/dL	TG <500 mg/dL	TLC	TLC + Fibrate or Niacin	Fibrate or Niacin
LDL 100-129 mg/dL	LDL <100 mg/dL	TLC	TLC + low dose Statin	Bile acid seq. or Niacin
LDL ≥130 mg/dL	LDL <100 mg/dL	TLC + low dose Statin	TLC + max. dose Statin	Bile acid seq. or Niacin
TG \geq 200 mg/dL and non-HDL \geq 130 mg/dL	Non-HDL <130 mg/dL	TLC + low dose Statin	TLC + max. dose Statin	Fibrate or Niacin

GUIDELINE 5

seq., sequestrant.

- 5.1 For adolescents with Stage 5 CKD and fasting triglycerides ≥500 mg/dL (≥5.65 mmol/L) that cannot be corrected by removing an underlying cause, treatment with therapeutic lifestyle changes (TLC) should be considered. (C)
- 5.2 For adolescents with Stage 5 CKD and LDL ≥130 mg/dL (≥3.36 mmol/L), treatment should be considered to reduce LDL to <130 mg/dL (<3.36 mmol/L). (C)
- 5.3 For adolescents with Stage 5 CKD and LDL <130 mg/dL (<3.36 mmol/L), fasting triglycerides ≥200 mg/dL (≥2.26 mmol/L), and non-HDL cholesterol (total cholesterol minus HDL) ≥160 mg/dL (≥4.14 mmol/L), treatment should be considered to reduce non-HDL cholesterol to <160 mg/dL (<4.14 mmol/L). (C)</p>

Treatment for Adolescents



Units for the figure above are in mg/dL. To convert mg/dL to mmol/L, multiply triglycerides by 0.01129 and LDL or non-HDL cholesterol by 0.02586. Abbreviations: TG, triglycerides; TLC, therapeutic lifestyle changes; LDL, low-density lipoportein; HDL, high-density lipoprotein.

The Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease, as well as all other K/DOQI guidelines, can be accessed on the Internet at www.kdoqi.org Am J Kidney Dis 41:S1-S92, 2003 (suppl 3)

The NKF gratefully acknowledges $\mathbf{A}_{\text{MORN}}^{\text{moments}}$, Founding and Principal Sponsor of K/DOQITM

© 2003 National Kidney Foundation, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the National Kidney Foundation. Permission requests should be written and addressed to the publications department of the National Kidney Foundation.



30 East 33rd Street New York, NY 10016 1-800-622-9010

Order No. K/DOQI 12-50-2110



Key Features of the NKF-K/DOQI Guidelines That Differ from Those of the National Cholesterol Expert Panel on Children

	F-KDOQI Guldelinen	в,	ent Panel <u>on Children</u>		
1.	Adolescents with CIOD should be considered to be in the highest risk onleggy.	1.	Adolescente with CKD ann not manuged differently from other patients.		
2	Evaluation of dyslipidemine should occur after presentation with CKD, after a change in lidnwy failure treatment modulity, and annusity.	2.	Evaluation of dysliphtemics should occur avery 5 years.		
3	HLDL is 130-169 mg/dL, start TLC det (if nutritional status is adequate), followed in 8 months by a static≪ if LDL ≥130 mg/dL.	8.	HLDL >130 mg/dL, start TLC Step I AHA diel, followed in 3 months by Step II AHA diel # LDL >180 mg/dL		
4.	li LDL ≥160 mg/dL, stari TLC pixe a stalin.	4.	FLDL ≥180 mg/dL and family history of CHD or two or more CVD risk factore, star <u>t drug therapy.</u>		
公司	To convert mg/d, to annucli, multiply triggoedies by 0.01189 and observed by 0.020 Mill statute, the charge detector. «Currently, normalistic is the only stallin approved by the U.S. Foot and Dug contribution for use in children. Alternatistical NKT-NOOCI, Hellowed Johny Foundation Military Disease Colorones Quality Installer; CMQ, chronic bibliogradiants: AKA-NOOCI, Hellowed Johny Foundation Military Disease Colorones Quality Installer; CMQ, chronic bibliogradiants: AKA-NOOCI, Hellowed Association; LDL, box density lippication challed at 71.27, chargewide Electric charges; CMQ, cardioversation disease.				

Therapeutic Lifestyle Changes (TLC) for Adults With Chronic Kidney

Diet (Consult a dietitian with expertise in chronic kidney disease)	Physical Activity
Emphasize reduced saturated fat: Saturated fat: <7% of total calories Polyunsaturated fat: up to 10% of total calories Monounsaturated fat: up to 20% of total calories Total fat: 25%-35% of total calories Cholesterol: <200 mg per day Carbohydrate: 50%-60% of total calories Emphasize components that reduce dyslipidemia Fiber: 20-30 g per day emphasize 5-10 g per day viscous (soluble) fiber Consider plant stanols/sterols 2 g per day Improve glycemic control Emphasize total calories to attain/maintain standard NHANES body weight Match intake of overall energy (calories) to	Moderate daily lifestyle activities Use pedometer to attain/maintain 10,000 steps per day Emphasize regular daily motion and distance (within ability) Moderate planned physical activity 3-4 times per week 20-30 minute periods of activity Include 5-minute warm-up and cool-down Choose walking, swimming, supervised exercise (within ability) Include resistance exercise training Emphasize lean muscle mass and reducing excess body fat
watch intex of overall energy features (to overall energy needs Body Mass Index 25-28 kg/m ² Waist circumference Men <40 inches (102 cm) Women <35 inches (88 cm) Waist-Hip Ratio (Men <1.0; women <0.8)	Habits Alcohol in moderation: limit one drink per day with approval of physician Smoking cessation
	Abbreviation: NHANES, National Health and Nutrition Examination Survey.

	Adjust for	_				
Agent	61-61	19-38	45	Koten		
Abnesistin	Na	No	Na			
Certrestatin	Na	10 60%	4 10 50%	Witnessen		
Florenskiller	7	?	7			
Lovadelin	No	↓ to 50%.	J 10 275.			
Proventation	No	Мо	Na			
Şimustalin	9	7	Ŷ	100 B		
Nicotinio sold	No	No	↓ to 50%	Sets binay examina		
Cholestipol	No	No	No	Not absorbed		
Choicetynanine	No	No	No	Not absorbed		
Colementum	No	No	No	Not absorbed		
Bezallerale	+ to 00%	1 16 25%	Arciti	Ney 1 serum conditions		
Collecte	4 to 80%	4 to 22%	Neeki	May Toerum creathing		
Configure	1	1	?	Nay 1 sature creativities		
Fercilizatio	↓ to 60%	↓625%	Andri	May † serves creativities		
Genflered	No	No -	No	May 🕆 servin creatining		
Abbendalboar Örfi, glonnedar Bladien nän.						

Recommended Daily Statin Dose Ranges^a

	Level of G	Level of GFR (mL/min/1.73 m ²)		
Statin	<u>></u> 30	≥ 30 <30 or dialysis		
Atorvastatin	10-80 mg	10-80 mg	10-40 mg	
Fluvastatin	20-80 mg	10-40 mg	10-40 mg	
Lovastatin	20-80 mg	10-40 mg	10-40 mg	
Pravastatin	20-40 mg	20-40 mg	20-40 mg	
Simvastatin	20-80 mg	10-40 mg	10-40 mg	

^aAdult Treatment Panel III recommendations for GFR \geq 30 mL/min/1.73 m². Most manufacturers recommend once daily dosing, but consider giving 50% of the maximum dose twice daily.

Effects of Cyclosporine on Blood Levels of Statins in Kidney Transplant Recipients

auto.	investor in the Quality's AUC	
Abovedalin	8-foid	
Certranialis*	5-foid	
Bininadaile	3-fold	
Sinevenicin	< 84obl	
Loverigin	240b	
Londain	3460	
Lousiain .	20-400	
Persetain	54ald	
Functols	2400	
4Windown, 450.05 Abbrovialist: AVC, and under the scanadicalist-line curve.		

Bile Acid Sequestrant Dose

Agent	Dasa Rango (g per day)
Choleolyconico	4-15
Colection	5-20
Colecevelern	2538

Relative Effect of Different Immunosuppressive Agents on Cardiovascular.

	AZA or MAF	Predalenne	Cyclosperine	Tasselleres	Şirgila ya
Hypertension	-	Ħ	f †	1	_
Dysipidemia	-	Ħ			. †† †
Diabates	-	1	^	††	·
Annes aller s ande, i	aniquettalle segui	os of the mission afte	ni of each agant un ca	do anula dasar	rink fasters.

Astrovisilien: AZA, austriapeter, Mill', ayoupterainin antisi.

Maximum Doses of Fibrates in Patients with Reduced Kidney Function

	Down (reg) by Lovel of GFR (rsLinin/1.78 m?)						
Fibraio	>00<	80-00	14-59	<16			
Bezzlibrete 200 tid 200 gd Avoid							
Calibrate	1,000 bid	1,000 qd	500 od	Avold			
Ciprolibrate	200 qd	7	. 9	7			
Fenolibrate	201 qd	134 qd	67 qd	Avoid			
Ganibrod	800 bid	(000 bid	COD bid	600 bid			
Abbrevialors GFA, glomeniar Braten min.							